SCHEMBL7516887

SCHEMBL7516887

COc1ccc(NS(=O)(=O)c2cc(Oc3c(C)cc(NC(=O)C(=O)O)cc3C)ccc2O)cc1

nearest known ligand 0.58

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
THRA P10827 2/20 0.58
THRB P10828 2/20 0.58
POLB P06746 2/20 0.47
GAA P10253 1/20 0.47
TSHR P16473 1/20 0.47
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
IDH1 O75874 1/20 0.46
BCL2L1 Q07817 1/20 0.44
MCL1 Q07820 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7514101 0.92 THRB (0.60) THRATHRBIDH1
SCHEMBL7513449 0.91 THRA (0.57) THRATHRBIDH1
SCHEMBL7516945 0.89 THRA (0.59) THRATHRBGAAALDH1A1SMN1; SMN2
SCHEMBL14489125 0.85 THRB (0.61) THRATHRB
SCHEMBL7511319 0.85 THRA (0.57) THRATHRBPOLB
SCHEMBL6655902 0.85 THRB (0.51) THRATHRBIDH1
SCHEMBL7516636 0.85 THRA (0.52) THRATHRB
SCHEMBL7511685 0.84 THRA (0.54) THRATHRBSMN1; SMN2IDH1
SCHEMBL7519124 0.84 THRA (0.61) THRATHRB
SCHEMBL6659909 0.84 THRA (0.66) THRATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2002540189-A 2002-11-26 JP claimed
US-20020107390-A1 Thyromimetic organic compounds KUKKOLA PAIVI J (US) 2002-08-08 US claimed
WO-2002032408-A2 COMBINATIONS OF A THYROMIMETIC COMPOUND AND A STATIN NOVARTIS AG (CH) 2002-04-25 WO claimed
US-20020045751-A1 Thyromimetic organic compounds NOVARTIS AG (CH) 2002-04-18 US claimed
EP-1165502-A1 DIARYL DERIVATIVES AND THEIR USE AS MEDICAMENTS Novartis AG (CH) 2002-01-02 EP claimed
WO-2000058279-A1 DIARYL DERIVATIVES AND THEIR USE AS MEDICAMENTS NOVARTIS AG (CH) 2000-10-05 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020045751-A1 Thyromimetic organic compounds TPO, THRA, LPO THRA 2/4885THRB 7/4885POLB 2342/4885
US-20020107390-A1 Thyromimetic organic compounds TSHR, NR1H3, NR1H2 THRA 4/4885THRB 5/4885POLB 3614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.